Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding
about
Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicatorMolecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interactionMolecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell functionThe acquisition of novel N-glycosylation sites in conserved proteins during human evolutionCell Adhesion Molecule CD166/ALCAM Functions Within the Crypt to Orchestrate Murine Intestinal Stem Cell Homeostasis.Quantitative membrane proteomics reveals new cellular targets of viral immune modulatorsCD166 regulates human and murine hematopoietic stem cells and the hematopoietic nicheGenome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanismsEnhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer.CD6 as a therapeutic target in autoimmune diseases: successes and challenges.Activated leukocyte cell adhesion molecule (ALCAM or CD166) modulates bone phenotype and hematopoiesis.CD6 attenuates early and late signaling events, setting thresholds for T-cell activationTissue non-specific alkaline phosphatase production by human dental pulp stromal cells is enhanced by high density cell cultureQuantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells.Molecular profiling of tumor-specific TH1 cells activated in vivo.Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population.Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responsesCritical factors in basal cell adhesion molecule/lutheran-mediated adhesion to laminin.Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.A model for sequestration of the transmission stages of Plasmodium falciparum: adhesion of gametocyte-infected erythrocytes to human bone marrow cells.Expression profiling of lymphocyte plasma membrane proteins.Neurolin Ig domain 2 participates in retinal axon guidance and Ig domains 1 and 3 in fasciculation.CD6 recognizes the neural adhesion molecule BEN.Cloning of the human activated leukocyte cell adhesion molecule promoter and identification of its tissue-independent transcriptional activation by Sp1.Identifying molecular phenotype of nucleus pulposus cells in human intervertebral disc with aging and degenerationCD6 as a potential target for treating multiple sclerosisMuSC, a novel member of the immunoglobulin superfamily, is expressed in neurons of a subset of cranial sensory ganglia in the mouse embryo.Immunomodulatory effects of soluble CD5 on experimental tumor models.Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer.
P2860
Q24806155-F54B8AF8-CD0F-4F00-8D2D-DCA881D2796DQ28212934-2D86034E-358E-4D00-AD2F-6A0B6BA06C77Q28288857-21ECE4D6-BD39-4A04-86CB-9E38F4861949Q28650549-F41BFF51-3678-487B-A825-688F4353FB91Q30846910-8658F649-F74E-4290-9E52-761A8869500BQ33269787-1DF3F854-7186-4188-9A33-08AABB021BE0Q33948700-43C67EF7-34C4-4F17-BBF1-C1477F3E75D7Q34209993-C54FF9E6-15D1-4741-A3E7-698AB4FDAA27Q34309546-752E4CC5-F38E-45E8-ABA7-7A9CFF61C795Q34337963-19753FAE-5AFE-4A0C-A51E-E1A7B5DF1972Q35630208-35E959BE-A475-47AA-9C73-21748FAC4552Q35818957-AC7041F6-4D49-41DF-83BD-79A62326918EQ35929341-C629F1CD-5545-456F-999E-956A75F6EAB4Q36440727-6A755FE1-4178-4646-AADC-4F8679BFD1D1Q36887852-9C37B22B-1E63-4E0D-B73E-2AA5E7377BD4Q37037637-33476FC5-5BA8-47AE-9CA2-9F454F3E82A2Q37483915-3D56A3B1-3FBB-46C1-8A3E-1A5BBF3C7AE5Q38329988-E3A1B7D9-ECB6-4C3D-970F-065CE203D4A5Q38730494-CCE3C062-BE98-4D15-B1F9-CA73AC70B0C4Q39241466-CA73E823-68F0-4C7B-B8D2-590E4D44EBB3Q39405774-BB24B825-B965-4B6A-8067-704AFE4A546DQ40624052-0F8983DD-B9C9-4CD3-84D9-88F05F54FA79Q41815601-159DF350-A6C5-43BB-B0B6-08AF287CFFF4Q41849984-D1E9BD88-0D8E-46D2-B8D5-A2AD4747C05BQ42021757-E01BBFC3-8333-4180-BD81-821F174C3880Q42056281-C44DBF01-C903-4DAB-A206-C8FE1FC6024AQ42177117-5B7213BC-E1FE-4D71-B050-11CAE140283EQ42819046-BB39E69A-E306-4A81-9936-D86D99FAC8F8Q47101681-6F129968-CA78-4011-9EFA-0EBE6E15CCE9Q48041020-FE7C11C4-0756-4A76-B746-25615032C072Q51311386-01C4A961-D358-4E26-AC63-C97B805C7CA3Q52571266-A9EC53D8-3165-4B33-9C8B-782FB26BECA0
P2860
Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
name
Characterization of mouse ALCA ...... mediates cross-species binding
@ast
Characterization of mouse ALCA ...... mediates cross-species binding
@en
Characterization of mouse ALCA ...... mediates cross-species binding
@nl
type
label
Characterization of mouse ALCA ...... mediates cross-species binding
@ast
Characterization of mouse ALCA ...... mediates cross-species binding
@en
Characterization of mouse ALCA ...... mediates cross-species binding
@nl
prefLabel
Characterization of mouse ALCA ...... mediates cross-species binding
@ast
Characterization of mouse ALCA ...... mediates cross-species binding
@en
Characterization of mouse ALCA ...... mediates cross-species binding
@nl
P2093
P356
P1476
Characterization of mouse ALCA ...... mediates cross-species binding
@en
P2093
A. W. Siadak
G. C. Starling
G. S. Whitney
J. Bajorath
M. A. Bowen
M. D'Egidio
P304
P356
10.1002/EJI.1830270625
P407
P50
P577
1997-06-01T00:00:00Z